Study Finds No Significant Difference in Dementia Risk Between GLP-1 RAs and DPP4 Inhibitors in Older Adults with Type 2 Diabetes
A recent study shows no significant difference in dementia risk among older adults with type 2 diabetes taking GLP-1 RAs or DPP4 inhibitors, highlighting the need for personalized treatment decisions.
Recent research published in the Annals of Internal Medicine indicates that for seniors with type 2 diabetes, the choice between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) does not significantly influence the risk of developing dementia. The study analyzed data from Medicare beneficiaries aged 66 and older who were using metformin and initiating either GLP-1 RAs or DPP4is between January 2017 and December 2018.
A total of 2,418 patients starting on GLP-1 RAs were compared to 4,836 matched patients initiating DPP4is, with the average age around 71 years. Over a median follow-up period of nearly two years, 96 patients in the GLP-1 group and 217 in the DPP4i group developed dementia. The analysis showed that at 30 months, the risk difference was approximately -0.93%, and the risk ratio was around 0.83, suggesting no definitive benefit of one medication class over the other in reducing dementia risk.
Interestingly, when examining age subgroups, there was a hint that younger seniors (under 75) might experience a somewhat lower risk with GLP-1 RAs, with a risk ratio of 0.64. However, for those aged 75 and older, the risk appeared slightly higher, with a risk ratio of 1.22. Despite these observations, the overall evidence does not establish a causal relationship between the type of diabetes medication and dementia prevention.
This study provides valuable insights for clinicians managing older adults with diabetes, emphasizing that the selection of GLP-1 RAs or DPP4is should consider other factors beyond dementia risk. Further research is needed to clarify potential age-related effects and underlying mechanisms.
Source: https://medicalxpress.com/news/2025-07-dementia-differ-glp-ras-dpp4is.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Therapy Targets Astrocytes to Enhance Immune Response Against Glioblastoma
A novel therapeutic approach aims to enhance immune responses against glioblastoma by targeting astrocytes that suppress T cell activity, potentially opening new avenues for treatment.
Potential Impact of Caffeine on Blood Transfusion Effectiveness
New research reveals that caffeine consumption by blood donors can impair red blood cell quality, potentially reducing the effectiveness of blood transfusions. The study highlights the importance of personalized transfusion strategies considering lifestyle factors and genetic traits.
Key Metric Identified to Improve Focused Ultrasound Treatment for High-Grade Gliomas
New research identifies a vital acoustic emission dose metric that could improve the safety and effectiveness of focused ultrasound treatments for brain tumors, enabling better drug delivery through the blood-brain barrier.
Updated Pediatric Venous Thromboembolism Treatment Guidelines Now Available
The American Society of Hematology and ISTH have published updated guidelines for managing pediatric venous thromboembolism, emphasizing new anticoagulant options and improved care strategies.